Beilinson Hospital has successfully completed a pilot program utilizing iCAD’s Artificial Intelligence technologies to enhance diagnostic capabilities for early detection of breast cancer in women over the age of 40. The program reviewed over 15,000 mammography scans and identified previously undetected tumors. It also helped in developing informed screening plans for individuals at risk of developing breast cancer, and can assess a patient’s risk level of developing a cancerous tumor in the next two years by scanning past dense tissue.
The iCAD program has received approval from the United States’ Food and Drug Administration (FDA) and has been deployed across the Clalit Health Services network, including its mammography units at hospitals and clinics nationwide. Dr. Ahuva Grubstein, Head of Beilinson’s Mammography Department, emphasized the importance of early detection and intervention in treating breast cancer, encouraging routine semi-annual mammography exams for women and those at risk of developing cancer. By using artificial intelligence as a tool to aid radiologists in scans, the reliability of the results increases, leading to more cases of early detection and potentially saving lives.
Since the launch of the pilot program, the technology has been utilized to assist radiologists in over 15,000 scans at Beilinson Hospital.
